Literature DB >> 19773638

Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases.

Nicolas Girard1, Charuhas Deshpande, Christopher Lau, David Finley, Valerie Rusch, William Pao, William D Travis.   

Abstract

The pathologic classification of nonsmall cell lung cancer (NSCLC) is evolving. Lung adenocarcinoma is morphologically heterogeneous, with mixtures of acinar, papillary, bronchioloalveolar, and solid patterns in more than 80% of cases. In case of synchronous or metachronous multiple NSCLC, the distinction of intrapulmonary metastases from independent primary tumors is of great clinical importance as it influences staging and potentially the therapeutic strategy. Here we took advantage of a cohort of 20 patients with 42 multiple NSCLC tumors (24 potential pair comparisons) that were annotated molecularly using genomic and mutational profiling to evaluate the value of comprehensive histologic assessment in this setting. Using the Martini-Melamed criteria, paired tumors were characterized as multiple primary NSCLCs in 21 cases and as intrapulmonary metastases in 3 cases. Genomic and mutational data led to a diagnosis of multiple primaries in 14 cases and of metastases in 8 cases; 2 cases could not be assessed. This molecular characterization contradicted the Martini-Melamed diagnosis in 7 (32%) of the 22 assessable comparisons. Adenocarcinoma was found in 32 (76%) of the 42 tumors. After review in a blinded fashion, semiquantitative comprehensive histologic assessment of paired tumors was different in 16 and similar in 8 paired tumors. We found that comparing adenocarcinomas is a complex issue that requires assessment not only of percentages of the histologic subtypes, but also the recording of additional histologic details such as cytologic features, patterns of stroma, necrosis, discrete nodularity versus miliary growth and variants such as clear cell, signet ring, mucinous, and fetal patterns. We also found that paired squamous cell carcinomas could be compared based on histologic subtyping in addition to cytologic and stromal characteristics. Considering histologically different tumors as multiple primaries, and similar tumors as metastases, comprehensive histologic subtyping was consistent with the molecular characterization in 20 (91%) of the 22 pairs comparisons. In summary, based on a well characterized cohort with detailed clinical, pathologic and molecular data, we found comprehensive histologic assessment is a powerful tool that seems to be a promising way to determine whether multiple lung adenocarcinomas or squamous cell carcinomas are metastatic or multiple primaries. This has great clinical implications for staging and therapeutic management of lung cancer patients with multiple tumors. Given its high correlation with molecular characterization of such tumors, it may provide a much cheaper and faster method to address this problem.

Entities:  

Mesh:

Year:  2009        PMID: 19773638      PMCID: PMC5661977          DOI: 10.1097/PAS.0b013e3181b8cf03

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  19 in total

1.  Multiple primary lung cancers.

Authors:  N Martini; M R Melamed
Journal:  J Thorac Cardiovasc Surg       Date:  1975-10       Impact factor: 5.209

2.  A metastasis or a second independent cancer? Evaluating the clonal origin of tumors using array copy number data.

Authors:  Irina Ostrovnaya; Adam B Olshen; Venkatraman E Seshan; Irene Orlow; Donna G Albertson; Colin B Begg
Journal:  Stat Med       Date:  2010-07-10       Impact factor: 2.373

Review 3.  Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions.

Authors:  Boudewijn J M Braakhuis; Maarten P Tabor; C René Leemans; Isaac van der Waal; Gordon B Snow; Ruud H Brakenhoff
Journal:  Head Neck       Date:  2002-02       Impact factor: 3.147

4.  Comparative genomic hybridisation as a supportive tool in diagnostic pathology.

Authors:  M M Weiss; E J Kuipers; S G M Meuwissen; P J van Diest; G A Meijer
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

5.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

6.  EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.

Authors:  Kentaro Inamura; Kengo Takeuchi; Yuki Togashi; Kimie Nomura; Hironori Ninomiya; Michiyo Okui; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Manabu Soda; Young Lim Choi; Toshiro Niki; Hiroyuki Mano; Yuichi Ishikawa
Journal:  J Thorac Oncol       Date:  2008-01       Impact factor: 15.609

Review 7.  The significance of intrapulmonary metastasis in non-small cell lung cancer: upstaging or downstaging? A re-appraisal for the next TNM staging system.

Authors:  Alberto Oliaro; Pier Luigi Filosso; Antonio Cavallo; Roberto Giobbe; Claudio Mossetti; Paraskevas Lyberis; Riccardo Carlo Cristofori; Enrico Ruffini
Journal:  Eur J Cardiothorac Surg       Date:  2008-05-27       Impact factor: 4.191

8.  Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.

Authors:  Noriko Motoi; Janos Szoke; Gregory J Riely; Venkatraman E Seshan; Mark G Kris; Valerie W Rusch; William L Gerald; William D Travis
Journal:  Am J Surg Pathol       Date:  2008-06       Impact factor: 6.394

9.  Lung cancer.

Authors:  W D Travis; L B Travis; S S Devesa
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

10.  The risk of second primary tumors after resection of stage I nonsmall cell lung cancer.

Authors:  David Rice; Hyung-Woo Kim; Anita Sabichi; Scott Lippman; J Jack Lee; Brendell Williams; Ara Vaporciyan; W Roy Smythe; Stephen Swisher; Garrett Walsh; Joe B Putnam; Waun Ki Hong; Jack Roth
Journal:  Ann Thorac Surg       Date:  2003-10       Impact factor: 4.330

View more
  57 in total

1.  The evolving role of the pathologist in the management of lung cancer.

Authors:  Adi F Gazdar
Journal:  Lung Cancer Manag       Date:  2012

2.  Classification of malignant and benign tumors of the lung by infrared spectral histopathology (SHP).

Authors:  Ali Akalin; Xinying Mu; Mark A Kon; Ayşegül Ergin; Stan H Remiszewski; Clay M Thompson; Dan J Raz; Max Diem; Benjamin Bird; Miloš Miljković
Journal:  Lab Invest       Date:  2015-02-09       Impact factor: 5.662

Review 3.  The pivotal role of pathology in the management of lung cancer.

Authors:  Morgan R Davidson; Adi F Gazdar; Belinda E Clarke
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

4.  Implications of the Eighth Edition of the TNM Proposal: Invasive Versus Total Tumor Size for the T Descriptor in Pathologic Stage I-IIA Lung Adenocarcinoma.

Authors:  Koji Kameda; Takashi Eguchi; Shaohua Lu; Yang Qu; Kay See Tan; Kyuichi Kadota; Prasad S Adusumilli; William D Travis
Journal:  J Thorac Oncol       Date:  2018-09-07       Impact factor: 15.609

5.  Tumor Spread Through Air Spaces Is a Predictor of Occult Lymph Node Metastasis in Clinical Stage IA Lung Adenocarcinoma.

Authors:  Raj G Vaghjiani; Yusuke Takahashi; Takashi Eguchi; Shaohua Lu; Koji Kameda; Zachary Tano; Jordan Dozier; Kay See Tan; David R Jones; William D Travis; Prasad S Adusumilli
Journal:  J Thorac Oncol       Date:  2020-01-30       Impact factor: 15.609

Review 6.  The 2011 IASLC/ATS/ERS pulmonary adenocarcinoma classification: a landmark in personalized medicine for lung cancer management.

Authors:  Yong Tang; Zhe He; Qihang Zhu; Guibin Qiao
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

7.  Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung.

Authors:  Rania G Aly; Natasha Rekhtman; Xiaoyu Li; Yusuke Takahashi; Takashi Eguchi; Kay See Tan; Charles M Rudin; Prasad S Adusumilli; William D Travis
Journal:  J Thorac Oncol       Date:  2019-05-20       Impact factor: 15.609

8.  Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung.

Authors:  Andrew G Nicholson; Kathleen Torkko; Patrizia Viola; Edwina Duhig; Kim Geisinger; Alain C Borczuk; Kenzo Hiroshima; Ming S Tsao; Arne Warth; Sylvie Lantuejoul; Prudence A Russell; Erik Thunnissen; Alberto Marchevsky; Mari Mino-Kenudson; Mary Beth Beasley; Johan Botling; Sanja Dacic; Yasushi Yatabe; Masayuki Noguchi; William D Travis; Keith Kerr; Fred R Hirsch; Lucian R Chirieac; Ignacio I Wistuba; Andre Moreira; Jin-Haeng Chung; Teh Ying Chou; Lukas Bubendorf; Gang Chen; Giuseppe Pelosi; Claudia Poleri; Frank C Detterbeck; Wilbur A Franklin
Journal:  J Thorac Oncol       Date:  2017-11-07       Impact factor: 15.609

9.  Assessment of chromosomal rearrangements helps to differentiate multiple lung primary cancers from metastases.

Authors:  Laura Bonanno; Alberto Pavan; Stefano Indraccolo
Journal:  Transl Lung Cancer Res       Date:  2019-12

Review 10.  Histopathologic and molecular approach to staging of multiple lung nodules.

Authors:  Frank Schneider; Sanja Dacic
Journal:  Transl Lung Cancer Res       Date:  2017-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.